Celltrion announced on the 4th that the results paper of the global clinical trial phase 3 on the interchangeability of the autoimmune disease treatment 'Yuplyma' (active ingredient adalimumab) and the original drug Humira has been published in the international journal 'Dermatology and Therapy'. This study is the result of the open-label extension study of Yuplyma alone, which was extended from the 27-week global clinical trial phase 3 conducted on Yeplyma and Humira to 52 weeks. The company previously conducted the global interchangeability phase 3 trial of Yuplyma, targeting 367 patients with moderate to severe plaque psoriasis, dividing them into two groups: the multi-cross dosing group of Yuplyma and Humira and the Humira maintenance dosing group, and compared pharmacokinetics, efficacy, safety, and immunogenicity between the groups for 27 weeks. As a result, the pharmacokinetic characteristics between the two groups were statistically equivalent, and similarities were observed in terms of efficacy and safety, the company explained. From the 27th week, both the multi-cross dosing group of Yuplyma and Humira and the Humira maintenance dosing group received Yuplyma alone. All results were consistently maintained throughout the open-label extension study period up to 52 weeks, regardless of previous dosing.
SD BIOSENSOR announced on the 4th that it has obtained the European In Vitro Diagnostic Medical Device Regulation certification (CE-IVDR certification) for five personal blood glucose monitoring products. The CE-IVDR certification has strengthened the safety, performance, and quality standards for in vitro diagnostic medical devices, and the company explained that this certification not only officially proves the excellence of its products but also enhances competitiveness in the global market. The products that received the CE-IVDR certification are SD CodeFree, STANDARD Mentor, STANDARD Mentor BT, STANDARD GlucoNavii GDH, and STANDARD GlucoNavii NFC. These products have improved the accuracy of blood glucose measurement using automated advanced laser pattern technology and self-developed gold electrode test strips.
Medytox Korea announced on the 4th that it received the ESG management award and the Minister of Health and Welfare award in the social contribution sector at the '2025 Korea Best Management Awards' held at The Plaza Hotel in Jung-gu, Seoul, on the 3rd. Medytox was recognized for its contributions to the sustainable development of the beauty industry through environmentally friendly practices, social responsibility, and organizational culture improvement. In the environmental sector, it contributes to managing the safety of discarded medical devices and promoting responsible medical culture through the 'Ulthera ESG Certification Hospital Campaign'. Additionally, it has created an employee-centered representative organization and has been carrying out social contribution activities through an in-house volunteer club.
The Korea Disease Control and Prevention Agency announced on the 4th that it met with a delegation led by the director of the National Center for Communicable Diseases (NCCD) of Mongolia to check the progress of international development cooperation (ODA) projects to strengthen response cooperation against infectious diseases. The agency has been promoting initiatives to strengthen Mongolia's capacity to manage infectious diseases in cooperation with the Yonsei University Industry-Academic Cooperation Foundation since 2023. This year, there will be mock training for preparation and response to new infectious diseases on-site, invitation training to strengthen investigation and monitoring capacity related to medical infections, and the 2nd Korea-Mongolia Joint Symposium.
The Korea Disease Control and Prevention Agency announced on the 4th that it will hold a 'Quarantine Idea Contest for Healthy Overseas Travel' from the 7th to the 27th to inform the importance of utilizing information for healthy overseas travel and voluntary participation in quarantine and reporting. The agency, along with 13 quarantine offices nationwide, is providing information on overseas infectious diseases for safe overseas travel, designating quarterly key quarantine management areas for intensive quarantine, and implementing pilot programs for respiratory infection testing services for travelers. This contest invites examples of effectively utilizing overseas infectious disease information, campaign proposals for preventing overseas infectious diseases, reasons for realizing the importance of quarantine, and ideas that can encourage voluntary reporting upon entry. The contest has three categories: video (short form), poster (image), and essay. There are no specific eligibility restrictions for participants.
The Korea Health Industry Development Institute K-Health Future Promotion Team announced on the 4th and 11th that it will hold a Proposal Day event to publicly announce the challenging problems of the 'Korean ARPA-H Project' and plan new tasks. The Korean ARPA-H Project is a challenging and innovative national research and development project aimed at solving difficult issues in the healthcare sector, including pandemic and essential medical crises. Before this event, the promotion team conducted a demand survey through an expert advisory group to identify healthcare challenges and selected five main missions. The challenging problems derived under the project managers (PM) for the five missions, including 'health security', 'overcoming uncured diseases', and 'essential medicine,' will be disclosed. The direction of planning new tasks for the Korean ARPA-H Project will also be revealed on that day.
Seoul National University Hospital announced on the 4th that Professor Hong Kyung-taek of the Department of Pediatrics and Adolescent Medicine received the 'Outstanding Researcher Award' at this year's International Conference of the Korean Society of Hematology (ICKSH). Since its inception in 2018, the ICKSH has been an international conference related to blood diseases attended by about 1,200 experts from approximately 35 countries each year. The Outstanding Researcher Award is given to the researcher under 45 years of age who has the most outstanding achievements based on representative papers published in domestic and international journals in the same year and recent research results. Professor Hong was recognized for his contributions to the treatment of hematologic cancers in children and adolescents.
The Korea Bio Association announced on the 4th that it held a 'Smart Start' investment attraction IR program for the first half of 2025 in collaboration with the New Industry Investment Group Council, co-hosted by the Ministry of Trade, Industry and Energy, to engage bio companies and professional investors together. Despite the global economic recession and investment shrinkage, key venture capitals and strategic investors participated in large numbers to secure growth momentum for promising bio companies. Pharmaceutical companies such as AHNGOOK PHARMACEUTICAL and Daewoong Pharmaceutical also participated as strategic investors.